Literature DB >> 8486770

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

M Sahni1, H L Guenther, H Fleisch, P Collin, T J Martin.   

Abstract

Bisphosphonates are generally considered to act on bone resorption by binding to bone mineral and subsequently inhibiting the activity of the osteoclasts which ingest them. This has been supported by the fact that bisphosphonates adsorbed on mineralized tissue inhibit the resorbing activity of isolated osteoclasts in vitro. However, the effectiveness of different bisphosphonates determined in this system does not reflect their relative potencies in vivo. Employing the well-described isolated osteoclast resorption pit assay, with ivory as the resorption substrate, we show here that this lack of correlation prevails only when the bisphosphonates are added to the mineral before addition of osteoclasts, but not when the cells are treated for a short time (5 min) before allowing them to adhere onto ivory. By using this approach with five different bisphosphonates, a stringent correlation of relative potencies was obtained with those found, both in the rat and in the human, in vivo. Furthermore, by using an osteoblastic cell line (CRP 10/30) which is a powerful promoter of osteoclastic resorption in vitro, we obtained evidence that the inhibitory effect of bisphosphonates was the result of an action on osteoblasts rather than on osteoclasts. Thus, in experiments in which the osteoblastic cells were pretreated for 5 min with bisphosphonates and then cocultured with osteoclasts, inhibition of osteoclastic resorbing activity was obtained. Moreover, it was found that this treatment resulted in a decrease of the stimulatory effect found in CRP 10/30-conditioned medium. In conclusion the present study shows that part of the osteoclast inhibiting action of the bisphosphonates is mediated through an action on osteoblasts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486770      PMCID: PMC288198          DOI: 10.1172/JCI116422

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.

Authors:  A Carano; S L Teitelbaum; J D Konsek; P H Schlesinger; H C Blair
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

2.  Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.

Authors:  M Sato; W Grasser
Journal:  J Bone Miner Res       Date:  1990-01       Impact factor: 6.741

3.  Prevention of postmenopausal bone loss by tiludronate.

Authors:  J Y Reginster; M P Lecart; R Deroisy; N Sarlet; D Denis; D Ethgen; J Collette; P Franchimont
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

4.  Evidence for heterogeneity of the osteoblastic phenotype determined with clonal rat bone cells established from transforming growth factor-beta-induced cell colonies grown anchorage independently in semisolid medium.

Authors:  H L Guenther; W Hofstetter; A Stutzer; R Mühlbauer; H Fleisch
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

5.  Prostaglandin E2 initially inhibits and then stimulates bone resorption in isolated rabbit osteoclast cultures.

Authors:  A Okuda; L M Taylor; J N Heersche
Journal:  Bone Miner       Date:  1989-11

6.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

7.  Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.

Authors:  R Valkema; F J Vismans; S E Papapoulos; E K Pauwels; O L Bijvoet
Journal:  Bone Miner       Date:  1989-01

8.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

Authors:  P M Boonekamp; L J van der Wee-Pals; M M van Wijk-van Lennep; C W Thesing; O L Bijvoet
Journal:  Bone Miner       Date:  1986-02

9.  Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages.

Authors:  M G Cecchini; R Felix; H Fleisch; P H Cooper
Journal:  J Bone Miner Res       Date:  1987-04       Impact factor: 6.741

10.  Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

Authors:  D E Hughes; B R MacDonald; R G Russell; M Gowen
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

View more
  72 in total

Review 1.  Bisphosphonates in the treatment of osteoporosis.

Authors:  N H Bell; R H Johnson
Journal:  Endocrine       Date:  1997-04       Impact factor: 3.633

Review 2.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

3.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

4.  Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain.

Authors:  Yuri Kato; Miki Hiasa; Reiko Ichikawa; Nao Hasuzawa; Atsushi Kadowaki; Ken Iwatsuki; Kazuhiro Shima; Yasuo Endo; Yoshiro Kitahara; Tsuyoshi Inoue; Masatoshi Nomura; Hiroshi Omote; Yoshinori Moriyama; Takaaki Miyaji
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

Review 5.  Preclinical pharmacology of alendronate.

Authors:  G A Rodan; J G Seedor; R Balena
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

6.  Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.

Authors:  Rebecca S Hayden; Moritz Vollrath; David L Kaplan
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

7.  Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.

Authors:  Z Zimolo; G Wesolowski; G A Rodan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion.

Authors:  J O Landman; S E Papapoulos
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

Review 9.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

10.  The diurnal rhythm of bone resorption in the rat. Effect of feeding habits and pharmacological inhibitors.

Authors:  R C Mühlbauer; H Fleisch
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.